TAG:
pathology consultant
New Esoteric Lab Firm Does Two Acquisitions
By Robert Michel | From the Volume XI No. 6 – April 26, 2004 Issue
CEO SUMMARY: Armed with $70 million, American Esoteric Laboratories (AEL) wants to build a national laboratory that offers a full menu of esoteric tests. It is building a primary laboratory in Dallas, which has one of the nation’s best air transport hubs. ThromboCare Laboratories and Vi…
“February 2, 2004 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XI No. 2 – February 2, 2004 Issue
Changes are afoot in the national market for anatomic pathology services. At AmeriPath, Inc., the search is on for a new CEO. Current Chairman and CEO, James C. New retired, effective February 1. The company has commenced the search for a new CEO. New had been with AmeriPath since it…
“October 15, 2001 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume VIII No. 14 – October 15, 2001 Issue
It’s a sign of the times for managed healthcare. Pacificare Health System, Inc. will offer its first preferred provider organization (PPO) health plan. the PPO is being marketed in California, Oklahoma, and Texas. Enrollment starts this month. Until now Pacificare’s business mode…
Competitive Dynamics In the Laboratory Testing Marketplace
By Robert Michel | From the Volume VII No. 18 – December 25, 2000 Issue
This section of the White Paper deals with the marketplace for laboratory services. For brevity and clarity, I will address five components: 1) independent commercial laboratories; 2) hospital-based laboratories; 3) esoteric, reference, and specialty testing laboratories; 4) anatomic pathology lab- o…
Year’s Ten Biggest Stories Reveal Modest Changes
By Robert Michel | From the Volume VII No. 17 – December 4, 2000 Issue
CEO SUMMARY: In many ways, 2000 was a relatively quiet year for laboratory organizations. This list of the ten biggest stories in the lab industry for 2000 demonstrates that the most innovative laboratory organizations in the United States are “raising the bar” for service and quality…
AmeriPath Will Acquire Inform DX for $44.6 Mil
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: It’s another example of consolidation in the anatomic pathology marketplace. AmeriPath, Inc.’s acquisition of Inform DX, Inc. positions the company to do as much as $350 million in revenues next year. By acquiring Inform DX, AmeriPath also gains entry into six more states…
Successful Specialty IPO Can Open Door for Others
By Robert Michel | From the Volume VII No. 14 – October 2, 2000 Issue
CEO SUMMARY: It’s no secret that a handful of laboratory companies would like to complete an initial public offering (IPO). If Specialty Labs’ public offering goes well, expect these lab companies to bring their own stock offerings to the public equity markets. As the number of public…
Merger Creates “New” Pathology Competitor
By Robert Michel | From the Volume VII No. 9 – June 19, 2000 Issue
CEO SUMMARY: Pathology business consolidation and regionalization continues. Pathology Consultants of America, Inc. (PCA) and PathSOURCE, Inc. announced their intention to merge last month. The combined company will be called Inform DX, Inc. and will compete nationally for anatomic pathol…
New CEO Takes Charge At Pathology Partners
By Robert Michel | From the Volume VII No. 8 – May 30, 2000 Issue
CEO SUMMARY: Pathology Partners, Inc. got a new President and CEO this month. The company is organized to build and operate independent regional histology and cytology laboratories in support of anatomic pathologists. Its business model is different than competing pathology companies and …
“May 30, 2000 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume VII No. 8 – May 30, 2000 Issue
Expect an announcement this week that Pathology Consultants of America, Inc. (PCA), based in Nashville, Tennessee, has acquired PathSOURCE, Inc. of Port Chester, New York. Both are single specialty physician practice management (PPM) companies devoted exclusively to …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized